Hetero, Zydus Settle Novartis MS Drug Suits Before IP Trial
Generic-drug makers Hetero and Zydus have each reached last-minute settlements to avoid an infringement trial set for Monday over their versions of Novartis Pharmaceuticals Corp.'s blockbuster multiple sclerosis drug Gilenya....To view the full article, register now.
Already a subscriber? Click here to view full article